Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: VidaMed

This article was originally published in The Gray Sheet

Executive Summary

VidaMed: Going public in an offering of 2.5 mil. shares of common stock, expected to be sold for about $10 per share. The Menlo Park, California-based developer of the TUNA transurethral needle ablation radiofrequency system expects to net about $22.6 mil. from the offering, $5 mil. of which is earmarked to fund ongoing clinical trials of TUNA for treatment of benign prostate hyperplasia. VidaMed started enrollment last fall for a 200-patient, blinded, randomized U.S. clinical trial of its system ("The Gray Sheet" Oct. 24, 1994, I&W-2). According to a prospectus for the IPO, approximately 50 patients have been enrolled in the trial thus far.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004209

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel